NCT03521154 · OUTCOME

Time to Second Subsequent Treatment

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) · Source last updated 2026-08-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: Months
Interval / dispersion: 95% Confidence Interval
Time frame: Time from randomisation to the start of second subsequent anti-cancer therapy or death. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months

What was measured

Time from the date of randomisation to the earlier of the second subsequent anti-cancer therapy start date following study drug discontinuation or death

Analysis population: Full analysis set

Groups in this outcome

Osimertinib

80mg once daily tablet

Placebo

Matching Placebo

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Osimertinib	143
Placebo	73

Reported measurements

Source class 1

Values in Months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Osimertinib	NA	Not reported	44.42	NA	NA - Not calculated as insufficient number of events to enable the median and upper limit of 95% confidence interval to be calculated
Placebo	47.38	Not reported	34.14	NA	NA - Not calculated as insufficient number of events to enable the upper limit of 95% confidence interval to be calculated

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

ci Lower Limit
0.28
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
0.91
estimate Comment
A hazard ratio \< 1 favours osimertinib
group Ids
OG000
OG001
non Inferiority Type
SUPERIORITY
p Value
0.022
param Type
Hazard Ratio (HR)
param Value
0.51
statistical Method
Log Rank

Complete source fields

analyses

ci Lower Limit
0.28
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
0.91
estimate Comment
A hazard ratio \< 1 favours osimertinib
group Ids
OG000
OG001
non Inferiority Type
SUPERIORITY
p Value
0.022
param Type
Hazard Ratio (HR)
param Value
0.51
statistical Method
Log Rank

classes

categories
measurements
comment
NA - Not calculated as insufficient number of events to enable the median and upper limit of 95% confidence interval to be calculated
group Id
OG000
lower Limit
44.42
upper Limit
NA
value
NA
comment
NA - Not calculated as insufficient number of events to enable the upper limit of 95% confidence interval to be calculated
group Id
OG001
lower Limit
34.14
upper Limit
NA
value
47.38

denoms

counts
group Id
OG000
value
143
group Id
OG001
value
73
units
Participants

description

Time from the date of randomisation to the earlier of the second subsequent anti-cancer therapy start date following study drug discontinuation or death

dispersion Type

95% Confidence Interval

groups

description
80mg once daily tablet
id
OG000
title
Osimertinib
description
Matching Placebo
id
OG001
title
Placebo

param Type

MEDIAN

population Description

Full analysis set

reporting Status

POSTED

time Frame

Time from randomisation to the start of second subsequent anti-cancer therapy or death. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months

title

Time to Second Subsequent Treatment

type

SECONDARY

unit Of Measure

Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice